Neuraxpharm Introduces a New Form of Medical Cannabis
Since November 2022, a new medication containing an active full-spectrum cannabis extract – Naxiva Panaxol from Neuraxpharm – has been available in the Czech Republic. The cannabis extract is offered in collaboration with Panaxia Labs Israel. Both companies are key players in the European medical cannabis market. Their agreement ensures the distribution of these products not only in the Czech Republic but also in Switzerland and Germany.
COMMERCIAL COMMUNICATION
Leader in CNS Disease Medications
Neuraxpharm is a European leader with 35 years of experience in developing medications for central nervous system (CNS) diseases. The company focuses on innovating existing drug forms and developing new modern treatments. Its portfolio includes more than 120 molecules addressing the treatment of depression, anxiety, Parkinson's and Alzheimer's diseases, epilepsy, schizophrenia, and other CNS disorders. Besides that, it also offers dietary supplements and nutraceuticals to help maintain normal brain function, nervous system, and mental functions.
Neuraxpharm develops, produces, and distributes established brands, value-added medicines, generics, medical cannabis, and orphan drugs, which are indicated for the treatment of rare diseases. Through its products, it targets a wide range of nervous system disorders while simultaneously striving to raise awareness about CNS diseases and reduce the associated stigmatization.
The company has direct representation in 20 European countries and collaborates with partners worldwide in the field of mental health and CNS diseases. Together with healthcare professionals and patient associations and through the Neurax Foundation, it aims to improve the life and mental well-being of patients with mental illnesses.
Education and Effort to Overcome Myths about Nervous System Diseases
Neuraxpharm’s concept is built from molecule development to market introduction, allowing for the flexible launch of new products, quick response to demand, and maintaining the highest quality standards. Simultaneously, it strives for a sustainable future by adopting integrated measures for responsible business operations and supporting families in need by understanding their needs within the community.
“Growing challenges in mental health caused by the pressures of modern life motivate us in our efforts to become a leader in the CNS field. We are committed to addressing the unmet needs of those struggling with psychiatric and neurological diseases and disorders and bringing more treatment options to more patients,” said Neuraxpharm CEO Dr. Jörg-Thomas Dierks.
An integral part of Neuraxpharm's activities is public education and the effort to overcome misconceptions about nervous system diseases and their treatment. The teams tirelessly work on developing educational campaigns and disseminating reliable and verified scientific content through websites and social media.
Extract-Based Medical Cannabis
The new drug Naxiva Panaxol is expected to help patients with chronic intractable pain. Its innovation lies in its new form. Unlike existing capsules, it will be prepared from a cannabis extract, which is simpler, less time-consuming, and allows for more precise dosing according to patient needs. It also simplifies use in other dosage forms, such as ointments, suppositories, or gels. Naxiva Panaxol is a standardized oil extract from medical cannabis Cannabis sativa L. About 170 specialists in the Czech Republic can prescribe it. The treatment is covered by all health insurance companies.
The Czech Republic is one of the most advanced countries in Europe in terms of the size of the medical cannabis market. The steady increase in the number of patients, doctors, and prescriptions issued over the past five years can be attributed to the subsidy of medical cannabis costs by health insurance. According to a report published by the Czech government agency for medical cannabis (SAKL), the number of prescriptions issued in our country increased by 37% in 2021 compared to 2020. Medical cannabis is most commonly prescribed to patients with chronic pain (80%), multiple sclerosis (12%), and Parkinson's disease. The report also shows that 61.8% of patients using medical cannabis in our country are women.
(asa)
Sources:
1. Neuraxpharm. Available at: www.neuraxpharm.com
2. Expansion in two new medical cannabis markets. Neuraxpharm, 2022 Oct 6. Available at: www.neuraxpharm.com/media/panaxia-and-neuraxpharm-to-enter-new-medical-cannabis-markets-in-europe
Did you like this article? Would you like to comment on it? Write to us. We are interested in your opinion. We will not publish it, but we will gladly answer you.
